Compare Bath & Body Works Inc (BBWI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Revvity Inc — how do they compare? Bath & Body Works Inc trades at $18.26 (market cap $3.81B), while Revvity Inc trades at $116.89 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 3.4× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| BBWI | RVTY | |
|---|---|---|
Market Cap | $3.81B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $31.87 | $117.75 |
52-Week Low | $14.85 | $82.26 |
Enterprise Value | $7.70B | $15.23B |
Dividend Yield | 4.24% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $18.28, down 5.38% over 24 hours, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics with a P/E of 5.36 and P/S of 0.54, while maintaining strong gross margins above 43%. Recent earnings have mostly beaten expectations, and the company is expanding internationally through partnerships with Ulta Beauty and entry into Brazil. Cash flow trends show improvement, with positive net cash flow projected for 2026.
The investment case hinges on BBWI's deep value proposition against declining revenue trends. Key opportunities include international growth and strategic partnerships, while risks involve high debt levels and ongoing revenue pressure. Analyst consensus is mixed with a $22.11 price target suggesting upside potential from current levels.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
